Latest news with #AndrewDudum
Yahoo
6 hours ago
- Business
- Yahoo
Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next
Hims & Hers (HIMS) is expanding its playbook across the Atlantic — the U.S.-based telehealth company announced Tuesday that it will acquire European telehealth platform Zava. The acquisition grows Hims & Hers' presence in the U.K. and gives the company a foothold in Germany, France, and Ireland, marking the company's biggest international move to date. The terms of the deal weren't disclosed, but the translation is an all-cash one expected to close later this year. Hims & Hers stock was up over 17% Tuesday morning — and is up an astounding 165% year to date. The deal adds more than 1.3 million active users to the company's existing 2.4 million subscriber base and positions Hims & Hers to roll out its digital healthcare model in some of Europe's largest healthcare markets. Weight-loss drugs will likely be a central part of that expansion. Andrew Dudum, Hims & Hers' CEO, told The Financial Times that there's a 'huge opportunity' in obesity, noting that Zava already offers branded weight-loss treatments and has seen growing demand. Hims & Hers is perhaps best known in the U.S. for its direct-to-consumer offerings across categories such as hair loss, sexual health, and anxiety — but its compounded GLP-1 medications have become one of its fastest-growing offerings. The company, which recently struck a deal to offer Novo Nordisk's Wegovy, has been threading a regulatory needle: offering custom formulations to a 'meaningfully smaller group of patients,' as CEO Andrew Dudum put it to The Financial Times. With the Zava deal, similar offerings could be on the horizon for Europe. In the U.K., compounded medications can legally be dispensed under certain conditions, providing an opening for Hims & Hers' approach. Lower pharmaceutical prices and public health system constraints could accelerate adoption. And with U.S. compounding regulations tightening and the branded supply stabilizing, international expansion could create a path for further growth. This isn't Hims & Hers' first international foray — the company acquired London-based Honest Health in 2021 — but the Zava deal adds an established European presence and could position Hims & Hers to build a branded footprint in key European markets while leveraging Zava's infrastructure. 'Early traction in the U.K. gives us confidence that we can scale our platform globally,' Dudum said on his company's recent earnings call. Zava CEO and co-founder David Meinertz will remain on board as general manager of the international business, and the Zava brand will reportedly stay live for a few quarters before rebranding as Hims & Hers. Meinertz said the deal could help ease pressure on Europe's strained healthcare systems. 'The medications are priced more competitively than in the U.S., so more people can actually afford it, and we are seeing a huge demand,' Meinertz told CNBC. 'The demand is increasing with additional strains on the statutory systems that telehealth can alleviate.' Hims & Hers is betting on that growing pressure on national health systems. 'Whether in rural towns, vibrant cities, or remote communities across Europe, people battling widespread, often silent chronic conditions like obesity, depression, and more will have access to the personalized, high-quality care they deserve,' Dudum said in the company's press release. 'The demand for simpler, more personalized healthcare is universal.' For the latest news, Facebook, Twitter and Instagram. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Business
- Yahoo
Hims Stock Surges 180%--Now It's Betting Big on Europe's $100B Weight-Loss Market
Hims & Hers Health (NYSE:HIMS) is doubling down on the global obesity drug boom. The U.S.-based telehealth company just snapped up European rival Zava in a cash deal, opening the door to 1.3 million new patients across the UK, Ireland, Germany, and France. CEO Andrew Dudum called obesity a huge opportunity and believes the path forward lies in personalized carenot just mass prescriptions. With demand already running hot for weight-loss treatments not covered by public healthcare, this acquisition could be Hims' ticket to scale its model far beyond U.S. borders. Warning! GuruFocus has detected 3 Warning Sign with HIMS. In the U.S., Hims built momentum by offering compounded versions of GLP-1 drugs like Wegovy and Zepbound during supply shortagesreplicas that mimicked the active ingredients but were tailored to individual needs. Even now, as shortages ease and compounding restrictions tighten, Hims hasn't exited the scene. Instead, it's pivoting toward more niche personalizations: lower doses, unique formulations, and side-effect-reducing combinations. That same playbook could be viable in the UK and Europe, where local rules still allow "specials"bespoke medications for patients with unique clinical needs. And here's the bigger picture: Hims isn't trying to replace branded drugsit's becoming the neutral platform that offers both. The company recently inked a deal with Novo Nordisk to sell Wegovy directly and expects more collaborations. Think of it like Switzerland: impartial, adaptive, and quietly positioning itself at the center of a lucrative market shift. With shares already up nearly 180% over the past year, investors could be looking at a business that's just getting startedespecially as Europe becomes its next frontier. This article first appeared on GuruFocus.
Yahoo
7 hours ago
- Business
- Yahoo
Hims Stock Surges 180%--Now It's Betting Big on Europe's $100B Weight-Loss Market
Hims & Hers Health (NYSE:HIMS) is doubling down on the global obesity drug boom. The U.S.-based telehealth company just snapped up European rival Zava in a cash deal, opening the door to 1.3 million new patients across the UK, Ireland, Germany, and France. CEO Andrew Dudum called obesity a huge opportunity and believes the path forward lies in personalized carenot just mass prescriptions. With demand already running hot for weight-loss treatments not covered by public healthcare, this acquisition could be Hims' ticket to scale its model far beyond U.S. borders. Warning! GuruFocus has detected 3 Warning Sign with HIMS. In the U.S., Hims built momentum by offering compounded versions of GLP-1 drugs like Wegovy and Zepbound during supply shortagesreplicas that mimicked the active ingredients but were tailored to individual needs. Even now, as shortages ease and compounding restrictions tighten, Hims hasn't exited the scene. Instead, it's pivoting toward more niche personalizations: lower doses, unique formulations, and side-effect-reducing combinations. That same playbook could be viable in the UK and Europe, where local rules still allow "specials"bespoke medications for patients with unique clinical needs. And here's the bigger picture: Hims isn't trying to replace branded drugsit's becoming the neutral platform that offers both. The company recently inked a deal with Novo Nordisk to sell Wegovy directly and expects more collaborations. Think of it like Switzerland: impartial, adaptive, and quietly positioning itself at the center of a lucrative market shift. With shares already up nearly 180% over the past year, investors could be looking at a business that's just getting startedespecially as Europe becomes its next frontier. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fast Company
8 hours ago
- Business
- Fast Company
Hims & Hers stock price jumps: Telehealth company acquires Zava, picking up over a million Europe customers
American telehealth company Hims & Hers Health announced on Tuesday that it will be acquiring Zava, a leading European digital health company in an all cash acquisition set to close in the second half of 2025. Following the announcement, Hims' stock price (HIMS) jumped 5.8% in premarket trading. (As of midday Tuesday, the stock was trading up just under one point.) The move will rapidly expand Hims & Hers' reach, which has a current base of 2.4 million U.S. customers. As the only digital health company with over a decade of operations across Germany, France, Ireland, and the U.K., Zava has an active user base of 1.3 million. 'The demand for simpler, more personalized healthcare is universal,' said Andrew Dudum, founder and CEO of Hims & Hers, in a press release. 'By leveraging Zava's established European presence, cutting-edge technology, and deep customer understanding, we're poised to fundamentally transform access to care for millions across Europe. Whether in rural towns, vibrant cities, or remote communities across Europe, people battling widespread, often silent chronic conditions like obesity, depression, and more will have access to the personalized, high-quality care they deserve.' Expanding to Europe is additionally beneficial because the E.U.'s universal healthcare policies make pharmaceuticals much more affordable relative to the U.S. This means that personalized telehealth services like Hims & Hers could become more widely accessible there. 'The medications are priced more competitively than in the U.S. so more people can actually afford it and we are seeing a huge demand,' said Zava CEO David Meinertz in an interview with CNBC. 'The demand is increasing with additional strains on the statutory systems that telehealth can alleviate.'
Yahoo
10 hours ago
- Business
- Yahoo
Hims & Hers Expands in Europe With Acquisition of ZAVA
Hims & Hers expanding in Europe with the purchase of London-based digital health platform ZAVA. The acquisition gives the health and wellness site an increased reach in the U.K., and launches the firm in Germany, France, and Ireland. The price of the all-cash deal was not & Hers Health (HIMS) shares rose Tuesday after the health and wellness site announced it was expanding its reach into Europe by buying London-based digital health platform ZAVA. The price of the all-cash deal was not disclosed. Hims & Hers explained that the purchase will increase its presence in the U.K., and give the firm an entry into Germany, France, and Ireland, "with more markets anticipated soon." Founder and CEO Andrew Dudum said by leveraging ZAVA's "established European presence, cutting-edge technology, and deep customer understanding, we're poised to fundamentally transform access to care for millions across Europe." The company added that it would soon introduce "a new, personalized dimension of digital health in Europe, providing individuals with access to care tailored to their specific needs and goals across dermatology, weight loss, sexual health and mental health." Hims & Hers noted that the acquisition would be paid for from the company's balance sheet, and is expected to close in the second half of this year. It expects the addition of ZAVA to be accretive by next year. Shares of Hims & Hers advanced about 3% in recent trading and have soared about 130% this year. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
